drugset
Drugs / L9LS
last change 11 days ago re-read 9 days ago

L9LS

also known as VRC-MALMAB0114-00-AB

Monoclonal antibody

Developed for
malaria · Plasmodium falciparum malaria
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · National Institutes of Health (NIH) · Indiana University · University of Washington · Harvard School of Public Health (HSPH) · Malaria Research and Training Center, Bamako, Mali
+6 more · University of the Sciences, Techniques and Technologies of Bamako · Centers for Disease Control and Prevention · Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS) · Liverpool School of Tropical Medicine · Kenya Medical Research Institute · University of Sciences, Techniques, and Technologies of Bamako (USTTB)

Trials 7

today NCT07208760 · Ph 2 NCT07060508 · Ph 2 NCT07082205 · Ph 3 NCT06461026 · Ph 1 NCT05816330 · Ph 2 NCT05400655 · Ph 2 NCT05304611 · Ph 2
202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06461026 Aug 2024 → Jun 2025 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 25 trials · 2 met primary
Phase 2 NCT07208760 Mar 2026 → Mar 2028 malaria National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 2 NCT07060508 Jul 2025 → Apr 2026 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT05816330 May 2023 → Feb 2024 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT05400655 Sep 2022 → Jun 2024 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed Met primary
Phase 2 NCT05304611 Mar 2022 → Apr 2024 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed Met primary
Phase 31 trial
Phase 3 NCT07082205 May 2025 → Sep 2026 overdue anemia, malaria Liverpool School of Tropical Medicine Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as L9LS “L9LS Antimalarial monoclonal antibodies (mMAbs)” NCT07082205 ↗
6

NCT07060508 ↗

NCT06461026 ↗

NCT05816330 ↗

NCT05400655 ↗

NCT07208760 ↗

NCT05304611 ↗
Known as VRC-MALMAB0114-00-AB “L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection” NCT05304611 ↗
1

“L9LS (VRC-MALMAB0114-00-AB)” NCT05816330 ↗
Action Inhibit “to neutralize it and prevent malaria infection” NCT07082205 ↗
Modality Monoclonal antibody “monoclonal antibody L9LS” PMID 38669354 ↗ Apr 2024
Route Subcutaneous “Administered one time via subcutaneous route.” NCT05304611 ↗